These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 33092743)

  • 21. Response to "COVID-19 and ACEI/ARB: Not Associated?".
    Schiffrin EL; Flack JM; Ito S; Muntner P; Webb RC
    Am J Hypertens; 2020 Aug; 33(8):789-790. PubMed ID: 32415836
    [No Abstract]   [Full Text] [Related]  

  • 22. COVID-19 and ACEI/ARB: Not Associated?
    Hajra A; Bandyopadhyay D
    Am J Hypertens; 2020 Aug; 33(8):788. PubMed ID: 32415832
    [No Abstract]   [Full Text] [Related]  

  • 23. Comment on "ACE inhibitors and COVID-19: We don't know yet".
    Ilcol TB; Cure E; Cumhur Cure M
    J Card Surg; 2020 Jun; 35(6):1387. PubMed ID: 32531125
    [No Abstract]   [Full Text] [Related]  

  • 24. Observational data during the COVID-19 pandemic: opportunity with uncertainty.
    Straw S; Witte KK
    Heart; 2020 Oct; 106(19):1461-1462. PubMed ID: 32759292
    [No Abstract]   [Full Text] [Related]  

  • 25. Renin-Angiotensin-Aldosterone System Inhibitors and Outcome in Patients With SARS-CoV-2 Pneumonia: A Case Series Study.
    Conversano A; Melillo F; Napolano A; Fominskiy E; Spessot M; Ciceri F; Agricola E
    Hypertension; 2020 Aug; 76(2):e10-e12. PubMed ID: 32383626
    [No Abstract]   [Full Text] [Related]  

  • 26. COVID-19: The heart of the issue.
    Woodward B; Kermali M
    J Card Surg; 2020 Aug; 35(8):2112. PubMed ID: 32542802
    [No Abstract]   [Full Text] [Related]  

  • 27. Cardiovascular disease and the impact of COVID-19.
    Yoganathan A; Sajjad MS; Harky A
    J Card Surg; 2020 Aug; 35(8):2113. PubMed ID: 32542799
    [No Abstract]   [Full Text] [Related]  

  • 28. Letter to the editors in response to: Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers may be harmful in patients with diabetes during COVID-19 pandemic (Cure et al.).
    Ekiz T; Kara M; Özçakar L
    Diabetes Metab Syndr; 2020; 14(4):525-526. PubMed ID: 32402930
    [No Abstract]   [Full Text] [Related]  

  • 29. Heartbeat: interaction of renin-angiotensin-aldosterone blocking drugs with COVID-19 disease susceptibility and severity.
    Otto CM
    Heart; 2020 Oct; 106(19):1451-1453. PubMed ID: 32928982
    [No Abstract]   [Full Text] [Related]  

  • 30. Renin-angiotensin-aldosterone system inhibitors to treat COVID-19?
    Henry RA
    CMAJ; 2020 Jun; 192(26):E728. PubMed ID: 32601254
    [No Abstract]   [Full Text] [Related]  

  • 31. Response to recent commentaries regarding the involvement of angiotensin-converting enzyme 2 (ACE2) and renin-angiotensin system blockers in SARS-CoV-2 infections.
    Speth RC
    Drug Dev Res; 2020 Sep; 81(6):643-646. PubMed ID: 32304146
    [No Abstract]   [Full Text] [Related]  

  • 32. [ACE-inhibitors, angiotensin receptor blockers and severe acute respiratory syndrome caused by coronavirus].
    Verdecchia P; Reboldi G; Cavallini C; Mazzotta G; Angeli F
    G Ital Cardiol (Rome); 2020 May; 21(5):321-327. PubMed ID: 32310915
    [TBL] [Abstract][Full Text] [Related]  

  • 33. In reply-Angiotensin-Converting Enzyme 2 and the Resolution of Inflammation: In Support of Continuation of Prescribed Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers.
    Sanchis-Gomar F; Lavie CJ; Perez-Quilis C; Henry BM; Lippi G
    Mayo Clin Proc; 2020 Jul; 95(7):1553-1556. PubMed ID: 32622458
    [No Abstract]   [Full Text] [Related]  

  • 34. Overlap Weighting: A Propensity Score Method That Mimics Attributes of a Randomized Clinical Trial.
    Thomas LE; Li F; Pencina MJ
    JAMA; 2020 Jun; 323(23):2417-2418. PubMed ID: 32369102
    [No Abstract]   [Full Text] [Related]  

  • 35. Controversial Relationship Between Renin-Angiotensin System Inhibitors and Severity of COVID-19: Announcing a Large Multicentre Case-Control Study in Italy.
    Di Castelnuovo A; De Caterina R; de Gaetano G; Iacoviello L
    Hypertension; 2020 Aug; 76(2):312-313. PubMed ID: 32383624
    [No Abstract]   [Full Text] [Related]  

  • 36. ACEing COVID-19: A Role for Angiotensin Axis Inhibition in SARS-CoV-2 Infection?
    Murthy VL; Koupenova M; Shah RV
    Circ Res; 2020 Jun; 126(12):1682-1684. PubMed ID: 32302248
    [No Abstract]   [Full Text] [Related]  

  • 37. Facts and reflections on COVID-19 and anti-hypertensives drugs.
    Marin GH
    Drug Discov Ther; 2020 May; 14(2):105-106. PubMed ID: 32213760
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Decreased Mortality of COVID-19 With Renin-Angiotensin-Aldosterone System Inhibitors Therapy in Patients With Hypertension: A Meta-Analysis.
    Guo X; Zhu Y; Hong Y
    Hypertension; 2020 Aug; 76(2):e13-e14. PubMed ID: 32458694
    [No Abstract]   [Full Text] [Related]  

  • 39. In-hospital use of ACEI/ARB is associated with lower risk of mortality and critic illness in COVID-19 patients with hypertension.
    Yuan Y; Liu D; Zeng S; Wang S; Xu S; Wang Y; Yu R; Gao Y; Li H; Feng X; Zhou N; Zhao C; Gao Q
    J Infect; 2020 Nov; 81(5):816-846. PubMed ID: 32800800
    [No Abstract]   [Full Text] [Related]  

  • 40. The interplay of hypertension, ACE-2 and SARS-CoV-2: Emerging data as the "Ariadne's thread" for the "labyrinth" of COVID-19.
    Tsioufis C; Dimitriadis K; Tousoulis D
    Hellenic J Cardiol; 2020; 61(1):31-33. PubMed ID: 32450334
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.